Mode
Text Size
Log in / Sign up
Phase 4 Completed N=45 Treatment

Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines

Source: ClinicalTrials.gov NCT00856414 ↗
Enrolled (actual)
45
Serious AEs
0.0%
Results posted
Dec 2011
Primary outcomePrimary: The First Visit Onset of Efficacy as Measured by Physician Assessment — 2.2 Number of Days

Summary

This study evaluates the patient satisfaction and onset of effect following treatment with botulinum toxin Type A in the treatment of glabellar rhytids (frown lines)

Outcome Measures

OutcomeResultp-value
PRIMARY
The First Visit Onset of Efficacy as Measured by Physician Assessment
2.2 —
PRIMARY
The First Visit Onset of Efficacy as Measured by Subject Assessment
1.84 —
SECONDARY
Average Subject Assessment Score in Improvement of Appearance of Frown Lines
1.73; 2.64 —
SECONDARY
Change From Baseline in Patient Satisfaction as Measured by Facial Line Outcome (FLO) Questionnaire Score
32.97; 38.55 —
SECONDARY
Percentage of Patients Reporting Self-Perception of Age (SPA)
22.2; 40.0; 37.8; 42.2; 44.4; 13.3 —

Eligibility Criteria

Inclusion Criteria

  • Female subjects of any race, 35-55 years of age
  • Moderate to severe glabellar wrinkles (lines between the eyebrows)

Exclusion Criteria

  • Previous botulinum toxin therapy
  • Subjects who are pregnant, breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control
  • Subjects planning a facial cosmetic procedure or visible scars
  • Previous cosmetic surgery to the upper face
  • Medical condition that may increase their risk of exposure to botulinum toxin including diagnosed Myasthenia Gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis, or any other disease that might interfere with neuromuscular function
  • History of facial nerve palsy
  • Allergy or sensitivity to any component of the study medication
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00856414). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search